Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab

Acta Ophthalmologica

Volumn 91, Issue 5, 2013, Pages

  De Geus, Stefan J R ^a   Jager, Martine J ^a   Luyten, Gré P M ^a   Dijkman, Greet ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; CLINICAL PRACTICE; CLINICAL PROTOCOL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXUDATIVE MACULAR DEGENERATION; HUMAN; INTRARETINAL CYST; INTRARETINAL FLUID; LETTER; MAJOR CLINICAL STUDY; NETHERLANDS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; SUBRETINAL FLUID; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; FEMALE; HUMANS; MACULA LUTEA; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84880303684     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12090     Document Type: Letter

References (5)

1. Almony A, Mansouri A, Shah GK, &, Blinder KJ, (2011): Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. Can J Ophthalmol 46: 182-185.
2. Gasperini JL, Fawzi AA, Khondkaryan A, et al., (2012): Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96: 14-20.
3. Gregori NZ, Feuer W, &, Rosenfeld PJ, (2010): Novel method for analyzing snellen visual acuity measurements. Retina 30: 1046-1050.
4. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, &, Jaffe GJ, (2011): Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897-1908.
5. Mitchell P, (2011): A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 27: 1465-1475.